Your browser doesn't support javascript.
loading
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.
Dovedi, Simon J; Elder, Matthew J; Yang, Chunning; Sitnikova, Suzanne I; Irving, Lorraine; Hansen, Anna; Hair, James; Jones, Des C; Hasani, Sumati; Wang, Bo; Im, Seock-Ah; Tran, Ben; Subramaniam, Deepa S; Gainer, Shelby D; Vashisht, Kapil; Lewis, Arthur; Jin, Xiaofang; Kentner, Stacy; Mulgrew, Kathy; Wang, Yaya; Overstreet, Michael G; Dodgson, James; Wu, Yanli; Palazon, Asis; Morrow, Michelle; Rainey, Godfrey J; Browne, Gareth J; Neal, Frances; Murray, Thomas V; Toloczko, Aleksandra D; Dall'Acqua, William; Achour, Ikbel; Freeman, Daniel J; Wilkinson, Robert W; Mazor, Yariv.
Afiliação
  • Dovedi SJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com.
  • Elder MJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Yang C; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Sitnikova SI; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Irving L; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Hansen A; Translational Science and Experimental Medicine, Respiratory and Immunology (RI), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Hair J; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jones DC; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hasani S; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Wang B; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Im SA; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Korea.
  • Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Subramaniam DS; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gainer SD; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Vashisht K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Lewis A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jin X; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Kentner S; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mulgrew K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Wang Y; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Overstreet MG; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Dodgson J; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Wu Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Palazon A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Morrow M; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Rainey GJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Browne GJ; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Neal F; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Murray TV; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Toloczko AD; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Dall'Acqua W; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland.
  • Achour I; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Freeman DJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Wilkinson RW; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mazor Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com.
Cancer Discov ; 11(5): 1100-1117, 2021 05.
Article em En | MEDLINE | ID: mdl-33419761
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados Limite: Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados Limite: Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article